8-K: Palisade Bio Reports 2023 Financial Results and Provides Corporate Update, Including Progress on PALI-2108

Palisade Bio announced its 2023 financial results, highlighted by a net operating loss of $13.1 million, and provided a corporate update, including the advancement of its lead program PALI-2108 towards a Phase 1 clinical study.

Summary

• Palisade Bio reported a net operating loss of $13.1 million for the year ended December 31, 2023, compared to a $15.7 million loss in 2022.
• The company's cash, cash equivalents, and restricted cash totaled $12.5 million as of December 31, 2023.
• Palisade Bio believes it has sufficient cash to fund operations into the first quarter of 2025.
• Research and development expenses increased by 5% to $6.9 million in 2023, primarily due to the Giiant License Agreement and increased employee costs.
• General and administrative expenses decreased by 26% to $6.2 million in 2023 due to cost-saving measures.
• The company is advancing its lead program, PALI-2108, for ulcerative colitis, with a Phase 1 clinical study expected to commence before the end of 2024.
• Palisade Bio formed a Clinical Advisory Board and appointed key opinion leaders.
• The company received $2.5 million in gross cash proceeds from the exercise of warrants in February 2024.
• A reverse stock split was approved by shareholders, with the ratio to be determined by the Board of Directors and implemented by December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's progress on its lead program, the formation of a clinical advisory board, and sufficient cash runway. However, the net loss and Nasdaq non-compliance notice temper the overall sentiment.

Positives

• The company's net operating loss decreased year-over-year, indicating improved financial performance.
• Palisade Bio has sufficient cash to fund operations into the first quarter of 2025.
• The company is on track to initiate a Phase 1 clinical study for PALI-2108 by the end of 2024.
• The formation of a Clinical Advisory Board with key opinion leaders enhances the company's expertise.
• The company secured $2.5 million in funding through the exercise of warrants.
• The company is actively developing a precision medicine approach to improve treatment outcomes.

Negatives

• The company reported a net operating loss of $13.1 million for 2023.
• The company received a notice from Nasdaq for not complying with audit committee requirements.
• Research and development expenses increased by 5% in 2023.

Risks

• The company is not in compliance with Nasdaq listing rules regarding the composition of its audit committee.
• The company's ability to advance its nonclinical and clinical programs is subject to risks and uncertainties.
• The company's ability to secure additional financing to fund future operations is a risk.
• The company is subject to the uncertain and time-consuming regulatory approval process.
• The company's future success depends on the success of its product candidates.

Future Outlook

Palisade Bio is focused on advancing PALI-2108 to a Phase 1 clinical study by the end of 2024 and developing a precision medicine approach. The company believes it has sufficient cash to fund operations into the first quarter of 2025.

Management Comments

• J.D. Finley, Chief Executive Officer, stated that 2023 was a transformative year for Palisade Bio as they strategically shifted into the autoimmune, inflammatory, and fibrotic disease space.
• J.D. Finley also commented that the company is on track to launch the Phase 1 study of PALI-2108 by the end of 2024.

Industry Context

Palisade Bio's focus on autoimmune, inflammatory, and fibrotic diseases aligns with a growing trend in the biopharmaceutical industry towards developing targeted therapies for these conditions. The company's precision medicine approach also reflects a broader industry shift towards personalized treatments.

Comparison to Industry Standards

• Palisade Bio's R&D spending of $6.9 million is relatively low compared to larger biotech companies in clinical stages, such as those with Phase 3 trials, which can spend tens or hundreds of millions annually.
• The company's cash runway into Q1 2025 is typical for pre-clinical stage companies, which often rely on additional funding rounds to progress through clinical trials.
• The net loss of $13.1 million is within the expected range for a company at this stage of development, where revenue is minimal and R&D costs are significant.
• The company's focus on a precision medicine approach is in line with industry trends, with companies like Foundation Medicine and Guardant Health leading in the development of biomarker-based diagnostics.

Corporate Governance

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split, which could affect the share price.
• Employees may be impacted by the company's cost-saving measures.
• Patients with ulcerative colitis may benefit from the development of PALI-2108.
• The company's suppliers and partners will be impacted by the company's progress and financial health.

Next Steps

• Complete ongoing IND/CTA-enabling tox studies by the end of the second quarter of 2024.
• Complete nonclinical IND/CTA-enabling activities by the end of the third quarter of 2024.
• Submit initial IND/CTA prior to the end of 2024.
• Initiate Phase 1a/b prior to the end of 2024.
• The company will need to regain compliance with Nasdaq listing rules regarding the composition of its audit committee.

Key Dates

Keywords

Palisade Bio, PALI-2108, Ulcerative Colitis, Clinical Trial, Phase 1, Financial Results, Reverse Stock Split, Nasdaq, Audit Committee, Biopharmaceutical, Autoimmune Disease, Inflammatory Disease, Fibrotic Disease